Ravichandran Karthikeyan, Bhoj R Singh*, Akanksha Yadav, Himani Agri, Varsha Jayakumar, Vinodhkumar OR, Dharmendra K Sinha

Division of Epidemiology, ICAR-Indian Veterinary Research Institute, Izatnagar, India

*Corresponding Author: Bhoj R Singh, Division of Epidemiology, ICAR-Indian Veterinary Research Institute, Izatnagar, India.

Received: December 12, 2022; Published: January 06, 2023

Abstract

Burkholderia cepacia complex (Bcc) bacteria are versatile difficult to treat pathogens with extraordinary metabolic diversity. They are important nosocomial pathogens having multi-drug resistant potential. Contamination and biofilm formation on medical devices and equipment are the important reasons for the multiple outbreaks in recent decades. In this study, we subjected 32 isolates of Bcc from ultrasound gels to the two important virulent traits such as antimicrobial susceptibility testing and biofilm producing ability with and without different stress conditions. All the isolates were susceptible to co-trimoxazole (TMP-SMX) (100%) suggesting it as the preferred drug or the drug of the first choice for treating Bcc infections. The isolates showed the varied degree of susceptibility to meropenem (91%), doxycycline (85%), gatifloxacin (85%), piperacillin+ tazobactam (82%), ceftazidime (79%), and levofloxacin (71%). Multiple antibiotic resistance (MAR) indices for all the isolates were >0.2 and three isolates had >0.5. Most of the Bcc isolates (81.25%) were weak biofilm producers, while three strains each of B.cepacia, B. cenocepacia and B. pseudomultivorans produced moderate and strong types of biofilms under standard laboratory conditions. The combination of change in pH with other stress conditions significantly increased the biofilm formation. This study found the difference in the antimicrobial susceptibility pattern of  Bcc isolates from ultrasound gels and the adaptability to in-vitro stress conditions explaining the variability of virulence among Bcc species.

Keywords: Burkholderia cepacia Complex (Bcc); Ultrasound Gels; Antimicrobial Susceptibility Testing; Multiple Antibiotic Resistance Index; Biofilm Formation; Stress Conditions

References

1. Sousa SA., et al. “Burkholderia cepacia complex: emerging multihost pathogens equipped with a wide range of virulence factors and determinants”. International journal of microbiology, 2011 (2011).
2. Branstetter JW., et al. “Management of cepacia syndrome with a combination of intravenous and inhaled antimicrobials in a non-cystic fibrosis pediatric patient”. The Journal of Pediatric Pharmacology and Therapeutics8 (2020): 730-734.
3. Wang L., et al. "An outbreak of Burkholderia stabilis colonization in a nasal ward”. International Journal of Infectious Diseases 33 (2015): 71-74.
4. Srinivasan S., et al. “Report on the newly emerging nosocomial Burkholderia cepacia in a tertiary hospital”. Medical Journal Armed Forces India 72 (2016): S50-S53.
5. Angrup Archana., et al. "Systematic review of ultrasound gel associated Burkholderia cepacia complex outbreaks: clinical presentation, causes and outbreak control”. American Journal of Infection Control (2022).
6. Leitão JH., et al. “Burkholderia cepacia complex infections among cystic fibrosis patients: perspectives and challenges”. Progress in Understanding Cystic Fibrosis 1 (2017).
7. “Performance Standards for Antimicrobial Susceptibility Testing”. 30^th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute; (2020).
8. Regan KH., et al. "Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis”. Cochrane Database of Systematic Reviews 4 (2019).
9. Flemming HC., et al. “Who put the film in biofilm? The migration of a term from wastewater engineering to medicine and beyond”. NPJ Biofilms and Microbiomes1 (2021): 1-5.
10. Vert M., et al. "Terminology for bio related polymers and applications (IUPAC Recommendations 2012)”. Pure and Applied Chemistry2 (2012): 377-410.
11. Tomlin K L., et al. "Interspecies biofilms of Pseudomonas aeruginosa and Burkholderia cepacia”. Canadian Journal of Microbiology10 (2001): 949-954.
12. , et al. "Evaluation of the efficacy of disinfection procedures against Burkholderia cenocepacia biofilms”. Journal of Hospital Infection 70.4 (2008): 361-368.
13. Peeters E., et al. “Transcriptional response of Burkholderia cenocepacia J2315 sessile cells to treatments with high doses of hydrogen peroxide and sodium hypochlorite”. BMC Genomics1 (2010): 1-18.
14. Jain N., et al. “Antimicrobial resistance in nosocomial isolates of Gram-negative bacteria: public health implications in the latvian context”. Antibiotics7 (2021): 791.
15. Shyamapada M., et al. "Bacteriological profiling of commercially available eye cosmetics and their antibiotic susceptibility pattern”. Translational Biomedicine3 (2016).
16. Akande EB., et al. "Antibiogram and plasmid profiling of resistance bacteria isolated from the blood of Hepatitis C Virus positive individuals”. Journal of Microbiology and Experimentation 7 (2019): 156-165.
17. , et al. "Studies on the involvement of the exopolysaccharide produced by cystic fibrosis-associated isolates of the Burkholderia cepacia complex in biofilm formation and in persistence of respiratory infections”. Journal of Clinical Microbiology 42.7 (2004): 3052-3058.
18. Coutinho C P., et al. "Burkholderia cenocepacia phenotypic clonal variation during a 3.5-year colonization in the lungs of a cystic fibrosis patient”. Infection and Immunity7 (2011): 2950-2960.
19. Singh A K., et al. "Standardization and classification of in vitro biofilm formation by clinical isolates of Staphylococcus aureus”. Journal of Global Infectious Diseases3 (2017): 93.
20. Stepanović S., et al. "A modified microtiter-plate test for quantification of staphylococcal biofilm formation”. Journal of Microbiological Methods2 (2000): 175-179.
21. Hassan A A., et al. "Variation of Burkholderia cenocepacia cell wall morphology and mechanical properties during cystic fibrosis lung infection, assessed by atomic force microscopy”. Scientific Reports1 (2019): 1-12.
22. Häfliger E., et al. "Systematic review of healthcare-associated Burkholderia cepacia complex outbreaks: presentation, causes and outbreak control”. Infection Prevention in Practice3 (2020): 100082.
23. Omar N., et al. "Microbiological assessment of Burkholderia cepacia complex (BCC) isolates in Alexandria Main University Hospital”. Alexandria Journal of Medicine1 (2015): 41-46.
24. Chang TH., et al. "Clinical characteristics and outcomes of non-cystic fibrosis patients with Burkholderia cepacia complex bacteremia at a medical center in Taiwan”. Journal of Microbiology, Immunology and Infection (2021).
25. Schaumburg F., et al. "Susceptibility of Burkholderia cepacia Complex to Ceftazidime/Avibactam and Standard Drugs of Treatment for Cystic Fibrosis Patients”. Microbial Drug Resistance5 (2022): 545-550.
26. , et al. "In vitro susceptibility of Burkholderia cepacia complex isolates: Comparison of disk diffusion, Etest^®, agar dilution, and broth microdilution methods”. Diagnostic Microbiology and Infectious Disease 86.4 (2016): 422-427.
27. , et al. "Clinical characteristics of bacteraemia caused by Burkholderia cepacia complex species and antimicrobial susceptibility of the isolates in a medical centre in Taiwan”. International Journal of Antimicrobial Agents 51.3 (2018): 357-364.
28. , et al. "In vitro activity of ceftazidime+ NXL104 against Pseudomonas aeruginosa and other non-fermenters”. Journal of Antimicrobial Chemotherapy 65.11 (2010): 2376-2381.
29. Papp-Wallace., et al. "Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients”. ACS Infectious Diseases7 (2017): 502-511.
30. Zhou J., et al. "Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis”. Antimicrobial Agents and Chemotherapy3 (2007): 1085-1088.
31. Abbott F K., et al. "Combination antimicrobial susceptibility testing of Burkholderia cepacia complex: significance of species”. International Journal of Antimicrobial Agents5 (2016): 521-527.
32. Van Dalem A., et al. "In vitro susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patients to ceftazidime-avibactam and ceftolozane-tazobactam”. Antimicrobial Agents and Chemotherapy9 (2018): e00590-18.
33. El Chakhtoura., et al. "A 17-year nationwide study of Burkholderia cepacia complex bloodstream infections among patients in the United States Veterans Health Administration”. Clinical Infectious Diseases (2017).
34. , et al. "Antibiotic resistance in Burkholderia species”. Drug Resistance Updates 28 (2016): 82-90.
35. Murphy M P., et al. "Residence in biofilms allows Burkholderia cepacia complex (Bcc) bacteria to evade the antimicrobial activities of neutrophil-like dHL60 cells”. Pathogens and Disease8 (2015).
36. Coenye T., et al. “Social interactions in the Burkholderia cepacia complex: biofilm formation and 2 quorum sensing”. Future Microbiology 5 (2010) :1087-1099.
37. Schwab U., et al. “Patterns of epithelial cell invasion by different species of the Burkholderia cepacia complex in well-differentiated human airway epithelia”. Infection and Immunity8 (2002). 4547-4555.
38. , et al. "The role of bacterial biofilms in chronic infections”. Apmis 121 (2013): 1-58.
39. Tate S., et al. "Airways in cystic fibrosis are acidified: detection by exhaled breath condensate”. Thorax11 (2002): 926-929.
40. Pezzulo Alejandro A., et al. "Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung”. Nature 7405 (2012): 109-113.
41. Massip-Copiz., et al. "Extracellular pH and lung infections in cystic fibrosis”. European Journal of Cell Biology6 (2018): 402-410.
42. Fischer Horst., et al. "Function of proton channels in lung epithelia”. Wiley Interdisciplinary Reviews: Membrane Transport and Signaling3 (2012): 247-258.
43. Pessi Gabriella, et al. "Response of Burkholderia cenocepacia H111 to micro-oxia”. PLoS One9 (2013): e72939.
44. Sass A M., et al. "The unexpected discovery of a novel low-oxygen-activated locus for the anoxic persistence of Burkholderia cenocepacia”. The ISME journal8 (2013): 1568-1581.

Citation

Citation: Bhoj R Singh., et al. “Antimicrobial Susceptibility Testing and Biofilm Production of Burkholderia cepacia Complex Organisms from Ultrasound Gels in India". Acta Scientific Microbiology 6.2 (2023): 27-36.

Copyright

Copyright: © 2022 Bhoj R Singh., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.